Drug intelligence / Profile preview

PAN007

Development stage: Preclinical
Lead developer: Pantherna Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

PAN007 is a preclinical mRNA-based therapeutic candidate being developed by Pantherna Therapeutics for the treatment of Acute Respiratory Distress Syndrome (ARDS) and COVID-19 pneumonia. The drug utilizes mRNA to encode Angiopoietin-1 (Ang1), a key ligand for the Tie2 receptor located on vascular endothelial cells. By promoting the activation of the Ang1-Tie2 signaling axis, PAN007 is designed to stabilize the vascular barrier and reduce the pathological capillary leakage and inflammation that characterize severe respiratory distress. This approach aims to restore endothelial function and improve clinical outcomes in patients with acute lung injury.

Targets

TEK (Angiopoietin-1 receptor)

Beyond the preview

Go deeper on PAN007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAN007.

Explore the full profile